List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. A novel biodegradable nerve conduit drug delivery device for peripheral nerverepair

    SBC: Microsurgical Innovations Inc            Topic: 999

    Project Summary Nerve injury can occur due to traumachronic compression or disease processes such as diabetes or tumors and have a tremendous socioeconomic impact from loss of work and healthcare costsThere is still a clinical need to improve recovery from nerve injuriesand a new nerve conduit drug delivery device that addresses this clinical need is the focus of the present proposalOur group has ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Continuous real-time fentanyl sensor platform based on smart hydrogels for application in anesthesia

    SBC: Sentiomed, Inc.            Topic: 300

    PROJECT SUMMARY ABSTRACT The opioid fentanyl is administered in millions of procedural sedations every yearIt is very potenthas large interpatient pharmacokinetic variabilityand routinely causes significant respiratory depression if bolused or not titrated judiciouslyDosing and timingcritical for safety and efficacyare presently only possible based on educated guesses and vital signsSedation assoc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Next generation HDAC inhibitors with superior potency, selectivity, and pharmacokinetic profiles for the treatment of liver ischemia-reperfusion injury

    SBC: Lydex Pharmaceuticals LLC            Topic: 300

    Hepatic ischemia reperfusion injuryIRIoccurs in many clinical situationssuch as traumahepatic surgerye gliver resection for tumor treatmentliver donation and transplantationshock and vascular diseasesHepatic I R causes severe liver injury and promotes inflammationleading to liver dysfunctionmultiple organ failure and deathIt also compromises long term outcomes after surgery and traumaCurrentlyno e ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of the GlycoFibrotyper for detection of liver fibrosis

    SBC: GlycoPath, LLC            Topic: 300

    Increasinglyalterations in N linked glycans have been reported for serum or plasmaor for the most abundant serum glycoproteinimmunoglobulin Gfrom large cohorts of samples representing rheumatoid arthritisdigestive diseasescancer and liver fibrosisIn the case of fibrosistwo tests have identified alterations in Nlinked glycosylation on both total IgG populations and on specific IgG moleculesBoth of ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ototoxici ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

    SBC: Translational Sciences Inc.            Topic: NHLBI

    Seventeen million people each year suffer from an ischemic stroke and millions are left dead and disabledTreatment with recombinant tissue plasminogen activatorr tPAis only modestly effective at reducing disability and it is associated with brain hemorrhage in up toof patients when serial imaging studies are performedBrain hemorrhage causes death and disability andis the major cause of early morta ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Fully Human Antibodies for the Prevention of Respiratory Syncytial Virus

    SBC: IDBiologics, Inc.            Topic: NIAID

    The goal of this STTR is to provide a preclinically validated monoclonal antibody or antibody combination for the prevention of respiratory syncytial virusRSVin high risk patients including infants and the elderlyWorldwideof children are infected with RSV before the age ofresulting in an estimatedmillion lower respiratory tract infectionsIn the United States adults overhavemillion RSV infections c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors

    SBC: Zylo Therapeutics Inc.            Topic: 400

    Radical prostatectomyRPis a commonly used treatment option for localized prostate cancerUnfortunatelythe procedure carries a risk of post surgical complications including a high risk of erectile dysfunctionEDThe main pathophysiological mechanism behind this is neuropraxia in which surgery either directly damages the cavernous nervesCNor does so indirectly through activation of an inflammatory resp ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Hierarchical, Layout-Aware, Radiation Effects Tools Vertically Integrated into an EDA Design Flow for Rad-Hard by Design

    SBC: Reliable MicroSystems, LLC            Topic: DTRA16A003

    The goal of this workis to establish a radiation-aware capability in a commercial EDA design flow that will enable first-pass success in radiation resiliency for DoD ASIC designs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications.Such an integrated capability does not presently exist.The ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  10. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government